中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2014年
3期
200-203
,共4页
胃肿瘤%药物治疗%紫杉醇脂质体%替吉奥%奥沙利铂
胃腫瘤%藥物治療%紫杉醇脂質體%替吉奧%奧沙利鉑
위종류%약물치료%자삼순지질체%체길오%오사리박
stomach neoplasms%drug therapy%paclitaxel liposome%S-1%oxaliplatin
目的：比较替吉奥或奥沙利铂联合紫杉醇脂质体治疗进展期胃癌的疗效及安全性。方法：将118例进展期胃癌患者随机分为两组，A组61例接受紫杉醇脂质体+替吉奥方案，B组57例接受紫杉醇脂质体+奥沙利铂方案；比较两组近期疗效、中位疾病进展时间、中位生存时间、体能状态和不良反应。结果：A组ORR、DCR、mTTP分别为31.1%、75.4%、4.2个月，B组分别为29.8%、71.9%、3.8个月，差异均无统计学意义（P>0.05）；两组mOS分别为10.5个月和8.9个月，差异有统计学意义（P<0.05）。B组Ⅲ～Ⅳ度腹泻及外周神经毒性发生率较A组严重（P<0.05）。结论：两种含紫杉醇脂质体化疗方案应用进展期胃癌的近期疗效相当，提示替吉奥/紫杉醇脂质体方案在总生存期和耐受性方面可能优于奥沙利铂/紫杉醇脂质体方案。
目的：比較替吉奧或奧沙利鉑聯閤紫杉醇脂質體治療進展期胃癌的療效及安全性。方法：將118例進展期胃癌患者隨機分為兩組，A組61例接受紫杉醇脂質體+替吉奧方案，B組57例接受紫杉醇脂質體+奧沙利鉑方案；比較兩組近期療效、中位疾病進展時間、中位生存時間、體能狀態和不良反應。結果：A組ORR、DCR、mTTP分彆為31.1%、75.4%、4.2箇月，B組分彆為29.8%、71.9%、3.8箇月，差異均無統計學意義（P>0.05）；兩組mOS分彆為10.5箇月和8.9箇月，差異有統計學意義（P<0.05）。B組Ⅲ～Ⅳ度腹瀉及外週神經毒性髮生率較A組嚴重（P<0.05）。結論：兩種含紫杉醇脂質體化療方案應用進展期胃癌的近期療效相噹，提示替吉奧/紫杉醇脂質體方案在總生存期和耐受性方麵可能優于奧沙利鉑/紫杉醇脂質體方案。
목적：비교체길오혹오사리박연합자삼순지질체치료진전기위암적료효급안전성。방법：장118례진전기위암환자수궤분위량조，A조61례접수자삼순지질체+체길오방안，B조57례접수자삼순지질체+오사리박방안；비교량조근기료효、중위질병진전시간、중위생존시간、체능상태화불량반응。결과：A조ORR、DCR、mTTP분별위31.1%、75.4%、4.2개월，B조분별위29.8%、71.9%、3.8개월，차이균무통계학의의（P>0.05）；량조mOS분별위10.5개월화8.9개월，차이유통계학의의（P<0.05）。B조Ⅲ～Ⅳ도복사급외주신경독성발생솔교A조엄중（P<0.05）。결론：량충함자삼순지질체화료방안응용진전기위암적근기료효상당，제시체길오/자삼순지질체방안재총생존기화내수성방면가능우우오사리박/자삼순지질체방안。
Objective:This study aimed to compare the efficacy and adverse reactions of two different chemotherapeutic regi-mens. In particular, chemotherapy with paclitaxel liposome was administered in combination with either S-1 or oxaliplatin as the first-line therapy of advanced gastric cancer. Methods:A total of 118 patients with advanced gastric cancer were randomly divided into groups A (61 cases) and B (57 cases). In group A, paclitaxel liposome combined with S-1 was administered;in group B, paclitaxel lipo-some combined with oxaliplatin was applied. The short-term efficacy, adverse reactions, Karnofsky performance status score, median time to progression (mTTP), and median overall survival (mOS) of the two groups were observed and compared. Results:No signifi-cant differences were observed in the objective response rate, disease control rate, and mTTP between groups A and B (31.1% vs. 29.8%, 75.4%vs. 71.9%, 4.2 months vs. 3.8 months;P>0.05). The mOS rates were 10.5 and 8.9 months in groups A and B, respectively, with statistically significant differences (P=0.006). The incidence of degreesⅢtoⅣdiarrhea and peripheral nerve toxicity was signifi-cantly higher in group B than in group A (P<0.05). No statistical differences were found between the two groups in terms of other side effects. Conclusion:The two paclitaxel liposome-based regimens showed similar therapeutic effect in patients with advanced gastric cancer. S-1/paclitaxel liposome treatment could be more effective in terms of mOS and had a tendency of lower toxicity.
